Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepalatide Combination Therapy in Chronic Hepatitis B
NCT05244057Phase 2Completed
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Hepalatide + TAF + PEG-IFN with Placebo + TAF + PEG-IFN (2 arms). Primary endpoint: Proportion of subjects with negative conversion of HBsAg at 56 weeks. Started Aug 2022; status: completed.
02
Drugs
hepalatide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05244057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244057.